PATIENTS WITH cutaneous lymphoma present to dermatologists with malignant exaggerations of cutaneous lymphocyte biological features.1 The puzzles presented by cutaneous T-cell lymphomas (CTCLs) are actively being pursued to understand and, one hopes, to exploit the regulation of cutaneous T cells. In the immunoregulatory repertoire of the skin are the answers to atopic dermatitis, psoriasis, contact sensitivity, and most inflammatory disorders that also present to dermatologists. The lure of understanding T-cell regulation by way of CTCL has even attracted criminal activities. One group of CTCL investigators was convicted of fraud when they uttered their version of "eureka."2 Still, there are few shouts of discovery. The answers can only be achieved in a stepwise approach. The accompanying article by Kim et al3 is a fitting memorial to the extent of information available from retrospective observational studies of CTCL. The key points of that article lead us to visualize the next steps: the mandates needed to explore the impact of therapy and the goals of therapy.
Heald PW. Memorials and Mandates for Cutaneous Lymphomas. Arch Dermatol. 2003;139(7):926-928. doi:10.1001/archderm.139.7.926